Cini John K. 4
4 · Sonnet BioTherapeutics Holdings, Inc. · Filed Feb 17, 2023
Insider Transaction Report
Form 4
Cini John K.
Chief Scientific Officer
Transactions
- Disposition to Issuer
Common Stock
2023-01-07−18,551→ 21,720 total - Award
Common Stock
2023-01-07+18,551→ 40,271 total
Footnotes (3)
- [F1]On December 14, 2022, the Reporting Person was granted 18,551 restricted stock units to be settled in shares of common stock, par value $0.0001. On January 7, 2023, the 18,551 restricted stock units granted to the Reporting Person were rescinded and canceled. On the same day, the Reporting Person was granted a restricted stock award of 18,551 shares of common stock. The shares in connection with the restricted stock award become fully vested on January 1, 2024, provided the Reporting Person remains in continuous service through such date.
- [F2]A Form 4 that was filed by the Reporting Person on December 22, 2022, incorrectly included amounts in Column 5 of Table I that did not reflect a 14:1 reverse stock split of the Issuer's common stock, effective September 16, 2022.
- [F3]Includes unvested restricted stock units.